| ¿ Qué hacemos? JS Osornio, RR Moscoso, JAÁ Funes, CAA Salinas, MAM Díaz, ... Enseñanza 2025, 2024 | | 2024 |
| “Air That Once Was Breath” Part 1: Wildfire-Smoke-Induced Mechanisms of Airway Inflammation–“Climate Change, Allergy and Immunology” Special IAAI Article Collection: Collegium … WS Bowman, RJ Schmidt, GK Sanghar, GR Thompson III, H Ji, AA Zeki, ... International Archives of Allergy and Immunology 185 (6), 600-616, 2024 | 1 | 2024 |
| “Air That Once Was Breath” Part 2: Wildfire Smoke and Airway Disease–“Climate Change, Allergy and Immunology” Special IAAI Article Collection: Collegium Internationale … WS Bowman, RJ Schmidt, GK Sanghar, GR Thompson III, H Ji, AA Zeki, ... International Archives of Allergy and Immunology 185 (6), 617-630, 2024 | | 2024 |
| 1157. Clinical safety, efficacy, and pharmacokinetics of fosmanogepix, a novel first-in-class antifungal, in patients with renal insufficiency: subset analysis from a phase 2 … P Bulpa, G Rahav, I Oren, M Aoun, GR Thompson III, P Pappas, ... Open Forum Infectious Diseases 7 (Supplement_1), S605-S605, 2020 | 5 | 2020 |
| 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITION IN POSACONAZOLE INDUCED HYPERTENSION AND HYPOKALEMIA W Yang, A Semrad, G Thompson Endocrine Practice 24, 16-17, 2018 | | 2018 |
| 1219. Utility of Plasma Microbial Cell-Free DNA Testing for Therapeutic Management and Antimicrobial Stewardship R Thompson, M Donnelley, GR Thompson, A Desai Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1059, 2023 | | 2023 |
| 1248. Efficacy and safety of oral Ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI) BD Alexander, O Cornely, P Pappas, R Miller, JA Vazquez, ... Open Forum Infectious Diseases 7 (Supplement_1), S642-S642, 2020 | 4 | 2020 |
| 1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with … GR Thompson III, JP Horcajada, JB Locke, R Viani, P Pappas, ... Open Forum Infectious Diseases 7 (Supplement_1), S657-S658, 2020 | 1 | 2020 |
| 144. MSG-15: Pharmacokinetic (PK), Adverse Events (AEs), and Tolerability Data from an Open Label Randomized Clinical Trial (RCT) Comparing Oral Suba-itraconazole (SUBA-ITC) to … PG Pappas, A Spec, MH Miceli, L Proia, AB Arauz, J Hayes, A Peinhardt, ... Open Forum Infectious Diseases 7 (Supplement_1), S202-S203, 2020 | 3 | 2020 |
| 1459 Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis G Thompson, S Wang, R Bercovitch, M Bolaris, D Van Den Akker, ... Open Forum Infectious Diseases 1 (suppl_1), S384-S385, 2014 | | 2014 |
| 147. clinical safety and efficacy of novel antifungal, fosmanogepix, in the treatment of candidemia: results from a phase 2 proof of concept trial P Pappas, BJ Kullberg, JA Vazquez, I Oren, G Rahav, M Aoun, P Bulpa, ... Open Forum Infectious Diseases 7 (Supplement_1), S203-S204, 2020 | 19 | 2020 |
| 1718. Rezafungin clinical safety and efficacy in patients with candidemia and/or invasive candidiasis in the randomized, double-blind, multicenter, phase 2 STRIVE study GR Thompson, J Vazquez, A Soriano, A Skoutelis, L Ostrosky-Zeichner, ... Open Forum Infectious Diseases 5 (suppl_1), S52-S52, 2018 | 5 | 2018 |
| 1718. The Natural History of Chronic Pulmonary Coccidioidomycosis in the Pre-Antifungal Era. AJ Freifeld, D Bays, GR Thompson, S Reef, L Snyder, JN Galgiani Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 2031. False-positive serologic results attributable to IVIG therapy KE Hanson, N Gabriel, I Mchardy, W Hoffmann, SH Cohen, R Welch, ... Open Forum Infectious Diseases 5 (Suppl 1), S591, 2018 | 3 | 2018 |
| 231. Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia … GR Thompson, A Soriano, OA Cornely, BJ Kullberg, M Kollef, JA Vazquez, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 309, 2022 | 1 | 2022 |
| 249. Characteristics and outcomes of cryptococcosis among patients with COVID-19 compared to non-COVID-19 controls DB Chastain, V Kung, S Golpayegany, BT Jackson, C Franco-Paredes, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 327, 2022 | | 2022 |
| 386. A Reexamination of Disseminated Coccidioidomycosis: The Natural History in the Pre-Antifungal Era D Bays, GR Thompson, S Reef, L Snyder, A Freifeld, M Wilson, J Galgiani Open Forum Infectious Diseases 5 (Suppl 1), S149, 2018 | 1 | 2018 |
| 388. New Observations in Coccidioidomycosis Serology I Mchardy, BT Dinh, D Bays, S Waldman, E Stewart, D Pappagianis, ... Open Forum Infectious Diseases 5 (suppl_1), S150-S150, 2018 | | 2018 |
| 393. Isavuconazole in the Treatment of Coccidioidal Meningitis A Heidari, M Quinlan, D Benjamin, I Mchardy, SH Cohen, RH Johnson, ... Open Forum Infectious Diseases 5 (Suppl 1), S152, 2018 | | 2018 |
| 3RD, NA POMBEJRA S, JAMKLANG M, BAUTOS JM AND GELLI A. 2014 K Vu, R Tham, JP Uhrig, GR Thompson Invasion of the central nervous system by Cryptococcus neoformans requires a …, 0 | 3 | |
Thomas F PattersonProfessor of Medicine, The University of Texas Health Science Center at San Antonio在 uthscsa.edu 的电子邮件经过验证
